Early stopping for benefit in national cancer institute-sponsored randomized phase III trials: The system is working

Journal of Clinical Oncology

Volumn 27, Issue 10, 2009, Pages 1543-1544

  Sargent, Daniel ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; FOLINIC ACID; LAPATINIB; OXALIPLATIN; TRASTUZUMAB;

ADD ON THERAPY; ADJUVANT THERAPY; BREAST CANCER; CANCER RESEARCH; CLINICAL PROTOCOL; CLINICAL TRIAL; COLORECTAL CANCER; CONTROL GROUP; EDITORIAL; EVIDENCE BASED PRACTICE; HUMAN; MONITORING; ONCOLOGY; OVERALL SURVIVAL; PATIENT PARTICIPATION; PHASE 3 CLINICAL TRIAL; PHYSICIAN; PRIORITY JOURNAL; REINFORCEMENT; RESEARCH ETHICS; TREATMENT WITHDRAWAL;

CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 63749114189     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.20.8611     Document Type: Editorial

References (16)

1. Freedman B: Equipoise and the ethics of clinical research. N Engl J Med 317:141-145, 1987
2. DeMets DL: Futility approaches to interim monitoring by data monitoring committees. Clinical Trials 3:522-529, 2006
3. Wheatley K, Clayton D: Be skeptical about unexpected large apparent treatment effects: The case of an MRC AML12 randomization. Control Clin Trials 24:66-70, 2003
4. Montori VM, Devereaux PJ, Adhikari NKJ, et al: Randomized trials stopped early for benefit: A systematic review. JAMA 294:2203-2209, 2005
5. Mueller PS, Montori VM, Bassler D, et al: Ethical issues in stopping randomized trials early because of apparent benefit. Ann Intern Med 146:878-881, 2007
6. Bassler D, Montori VM, Briel M, et al: Early stopping of randomized clinical trials for overt efficacy is problematic. J Clin Epidemiol 61:241-246, 2008
7. Wilcox RA, Djulbegovic B, Guyatt GH, et al: Randomized trials in oncology stopped early for benefit. J Clin Oncol 26:18-19, 2008
8. Pocock S, White I: Trials stopped early: Too good to be true? Lancet 353:943-944, 1999
9. Freidlin B, Korn EL: Stopping clinical trials early for benefit: Impact on estimation. Clinical Trials (in press)
10. Piantadosi S: Rigor in monitoring clinical trials is ethical. J Clin Oncol 26:683-685, 2008
11. Ellenberg S, Fleming T, DeMets D: Data Monitoring in Clinical Trials: A Practical Perspective. Hoboken, NJ, John Wiley & Sons, Inc. 2002
12. Korn EL, Freidlin B, Mooney M: Stopping or reporting early for positive results in randomized clinical trials: The National Cancer Institute Cooperative Group Experience from 1990 to 2005. J Clin Oncol 27:1712-1721, 2009
13. de Gramont A, Boni C, Navarro M, et al: Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: Efficacy results with a median follow-up of 4 years. J Clin Oncol 23:246s, 2005 (suppl; abstr 3501)
14. de Gramont A, Boni C, Navarro M, et al: Oxaliplatin/5U/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years. J Clin Oncol 25:165s, 2007 (suppl; abstr 4007)
15. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673-1684, 2005
16. O'Brien PC, Fleming TR: A multiple testing procedure for clinical trials. Biometrics 35:549-556, 1979